LEPTIN AND OBESITY – NEUROENDOCRINE , METABOLIC AND ATHEROGENIC EFFECTS OF LEPTIN

  • Mišo Šabovič Klinični oddelek za žilne bolezni Interna klinika Klinični center Riharjeva 24 1000 Ljubljana
  • Alenka Mavri Klinični oddelek za žilne bolezni Interna klinika Klinični center Riharjeva 24 1000 Ljubljana
Keywords: leptin, body weight, obesity, atherosclerosis, treatment

Abstract

Background. Leptin is an adipocyte-derived hormone that was recently discovered. Leptin and leptin resistance play an important role in the pathogenesis of obesity. Leptin acts by binding to specific receptors in the hypothalamus to alter the expression of several neuropeptides that regulate food intake and energy expenditure. As commonly found, obese persons have leptin resistance and consequently attenuated effects of leptin. Mechanism underlying leptin resistance has not been explained yet: it might be the result of a receptor or post receptor defect, impaired transport of leptin through cerebrovascular barrier or inactivation of leptin by binding proteins. Phase I and II clinical trials proved that recombinant leptin administration to humans is safe. First results of the current phase III clinical trials demonstrated that leptin is moderately effective in the treatment of obesity.

Conclusions. Beside anti-obesity effect, leptin can have important metabolic and neuroendocrine effects. It is involved in glucose metabolism and insulin secretion, pathogenesis of polymetabolic syndrome, diabetes and arterial hypertension. In addition it affects some processes of atherothrombosis. It interacts with and significantly influences hypothalamic-pituitaryadrenal, thyroid, sexual glands and growth hormone axes. Explaining the mechanism of leptin resistance could be important for understanding the pathogenesis of obesity and associated pathologic states as polymetabolic syndrom, diabetes, arterial hipertension and atherothrombosis.

Downloads

Download data is not yet available.

References

Kormar L. The growing epidemic of obesity. NJ Med 2002; 99: 30–8.

Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. J Am Med Assoc 1999; 282: 1523–9.

Alisson DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths atributable to obesity in the United States. JAMA 1999; 282: 1530–8.

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425–32.

Zhang F, Babinski MB, Beals JM et al. Crystal structure of the obese protein leptin-E100. Nature 1997; 387: 206–9.

Cinti S, Frederick RC, Zingaretti MC et al. Immunohistochemical localization of leptin and uncoupling protein in white and brown adipose tissue. Endocrinology 1997; 138: 797–804.

Masuzaki H, Ogawa Y, Sagawa WN et al. Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat Med 1997; 3: 1029–33.

Lonnqvist F, Nordfors L, Jansson M, Thorne A, Schalling M, Arner P. Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. J Clin Invest 1997; 99: 2398–404.

Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292–5.

Kolaczynski JW, Considine RV, Ohannesian J et al. Responses of leptin to short term fasting and refeding in humans. Diabetes 1996; 45: 1511–5.

Kolaczynski JW, Ohannesian J, Considine RV, Marco CC, Caro JF. Response of leptin to short-term and prolonged overfeeding, fasting and refeeding in humans. J Clin Endocrinol Metab 1996; 81: 4162–5.

Mantzoros CS, Prasad AS, Beck F et al. Zinc may regulate serum leptin concentrations in humans. J Am Coll Nutr 1998; 17: 270–5.

Donahoo WT, Jensen TR, Yost TJ, Eckel RH. Isoproterenol and somatostatin decrease plasma leptin in humans: a novel mechanism regulating leptin secretion. J Clin Endocrinol Metab 1997; 82: 4139–43.

Miell JP, Englaro P, Blum WF. Dexamethasone induces an acute and sustained rise in circulating leptin levels in normal human subjects. Horm Metab Res 1996; 28: 704–7.

Malmström R, Taskinen MR, Karonen SL, Yki-Järvinen H. Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. Diabetologia 1996; 45: 1364–6.

Mantzoros CS, Moschos S, Avramopoulos I et al. Leptin concentrations in relation to body mass index and the tumor necrosis factor-α system in humans. J Clin Endocrinol Metab 1997; 82: 3408–13.

Janik JE, Curti BD, Considine RV et al. Interleukin 1α increases serum leptin concentrations in humans. J Clin Endocrinol Metab 1997; 82: 3084–6.

Grunfeld C, Zhao C, Fuller J et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996; 97: 2152– 7.

Saad MF, Damani S, Gingerich RI et al. Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab 1997; 82: 579–84.

Rosenbaum M, Nicolson M, Hirsch J et al. Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab 1996; 81: 3424–7.

Licinio J, Mantzoros C, Negrao AB et al. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. Nat Med 1997; 3: 575–9.

Sinha MK, Sturis J, Ohannesian J et al. Ultradian oscillations of leptin secretion in humans. Biochem Biophys Res Commun 1996; 228: 733–8.

Tartaglia L. The leptin receptor. J Biol Chem 1997; 272: 6093–6.

Tritos N, Mantzoros CS. Leptin: its role in obesity and beyond. Diabetologia 1997; 40: 1371–9.

Wolf G. Neuropeptides responding to leptin. Nutr Rev 1997; 55: 85–8.

Flier JS, Maratos-Flier E. Obesity and the hypothalamus: novel peptides for new pathways. Cell 1998; 92: 437–40.

Yu WH, Kimura M, Walczewska A, Karanth S, McCann SM. Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci USA 1997; 94: 1023–8.

Kristensen P, Judge ME, Thim L et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 1998; 393: 72–6.

Ur E, Grossman A, Despres JP. Obesity results as a consequence of glucocorticoid induced leptin resistance. Horm Metab Res 1996; 28: 744–7.

Caro JF, Kolaczynski JW, Nyce MR et al. Decreased cerebrospinal-fluid/ serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348: 159–61.

Cumin F, Baum HP, Levens N. Leptin is cleared from the circulation primarily by the kidney. Int J Obes Relat Metab Disord 1996; 20: 1120–6.

Mantzoros CS. Leptin and the hypothalamus: neuroendocrine regulation of food intake. Mol Psychiatry 1999; 4: 8–12.

Wang ZW, Zhou YT, Kakuma T et al. Comparing the hypothalamic and extrahypothalamic actions of endogenous hyperleptinemia. Proc Natl Acad Sci USA 1999; 96: 10373–8.

Iqbal J, Pompolo S, Considine RV, Clarke IJ. Localization of leptin receptorlike immunoreactivity in the corticotropes, somatotropes, and gonadotropes in the ovine anterior pituitary. Endocrinology 2000; 141: 1515–20.

Toni R, Jackson IM, Lechan RM. Neuropeptide-Y-immunoreactive innervation of thyrotropin-releasing hormone-synthesizing neuron in the rat hypothalamic paraventricular nucleus. Endocrinology 1990; 126: 2444–53.

Carro E, Seoane LM, Senaris R, Considine RV, Casanueva FF, Dieguez C. Interaction between leptin and neuropeptide Y on in vivo growth hormone secretion. Neuroendocrinology 1998; 68: 187–91.

Chan JL, Mantzoros CS. Leptin and the hypothalamic-pituitary regulation of the gonadotropin-gonadal axis. Pituitary 2001; 4: 87–92.

Ahima RS, Prabakaran D, Mantzoros CS et al. Role of leptin in neuroendocrine response to fasting. Nature 1996; 382: 250–2.

Mantzoros CS. Obesity eating disorders and restrained eating: is leptin the missing link? Mol Psychiatry 1997; 2: 377–80.

Audi L, Mantzoros CS, Vidal-Puig A, Vargas D, Guuussinye M, Carrascosa A. Leptin in relation to the resumption of menses in women with anorexia nervosa. Mol Psychiatry 1998; 3: 544–7.

Mantzoros CS, Moschos S, Avramopoulos I et al. Leptin concentrations in relation to body mass index and the tumor necrosis factor-α system in humans. J Clin Endocrinol Metab 1997; 82: 3408–13.

Yarasheski KE, Zachwieja JJ, Horgan MM, Powderly WG, Santiago JV, Landt M. Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity. Metabolism 1997; 46: 303–5.

Wauters M, Mertens I, Chagnon M et al. Polymorphisms in the leptin receptor gene, body composition and fat distribution in overweight and obese women. Int J Obes Relat Metab Disord 2000; 25: 714–20.

Echwald SM, Sorensen TD, Sorensen TI et al. Amino acid variants in the human leptin receptor: lack of association to juvenile onset obesity. Biochem Biophys Res Comm 1997; 233: 248–52.

Considine RV, Considine EL, Williams CJ et al. Mutation screening and identification of a sequence variation in the human of gene coding region. Biochem Biophys Res Commun 1996; 220: 735–9.

Caro JF, Kolaczynski JW, Nyce MR et al. Decreased cerebrospinal-fluid/ serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348: 159–61.

Van Heek M, Compton DS, France CF et al. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997; 99: 385–90.

Sinha MK, Opentanova I, Ohannesian JP et al. Evidence of free and bound leptin in human circulation-studies in lean and obese subjects and during short-term fasting. J Clin Invest 1996; 98: 1277–82.

Mavri A, Stegnar M, Šabovič M. Do baseline serum leptin levels predict weight regain after dieting in obese women? Diab Obes Metab 2001; 3: 293– 6.

Smiley T, Oh P, Shane LG. Relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes: a systematic review. Can J Cardiol 2001; 17: 797–805.

Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996; 45: 987– 91.

Saladin R, De Vos P, Guerre-Millo M et al. Transient increase in obese gene expression after food intake or insulin administration. Nature 1995; 377: 527–9.

Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996; 45: 987– 91.

Muzzin P, Eisensmith RC, Copeland KC, Woo SL. Correction of obesity and diabetes in genetically obese mice by leptin gene therapy. PNAS 1996; 93: 14804–8.

Sivitz WI, Walsh SA, Morgan DA, Thomas MJ, Haynes WG. Effects of leptin on insulin sensitivity in normal rats. Endocrinol 1997; 138: 3395–401.

Zimmet P, Alberti K. Leptin: is it important in diabetes? Diabetic Medicine 1996; 13: 501–3.

Taylor SI, Barr V, Reitman M. Does leptin contribute to diabetes caused by obesity. Science 1996; 274: 115–2.

Leclercq-Meyer V, Considine RV, Sener A, Malaisse WJ. Do leptin receptors play a functional role in the endocrine pancreas? Biochem Biophys Res Commun 1996; 229: 794–8.

Widjaja A, Stratton IM, Horn R, Holman RR, Turner R, Brabant G. Plasma leptin, obesity, and plasma insulin in type 2 diabetes subjects. J Clin Endocrinol Metab 1997; 82: 654–7.

Seufert J, Kieffer TJ, Leech CA et al. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 760–6.

Shek EW, Brands MW, Hall JE. Chronic leptin infusion in chrisis arterial pressure. Hypertension 1998; 31: 409–14.

Montani JP, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes Relat Metab Disord 2002; 26: Suppl 2: S28–38.

Constantinides S, Schaefer K, Loskutoff DJ. The prothrombotic effect of leptin. Possible implications for the risk of cardiovascular disease in obesity. Ann NY Ac Sci 2001; 947: 134–42.

Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999; 13: 1231–8.

O’Rourke L, Yeaman S, Shepherd PR. Insulin and leptin acutely regulate cholesterol ester metabolism in macrophages by novel signaling pathways. Diabetes 2001; 50: 955–61.

Mavri A, Stegnar M, Krebs M, Sentočnik JT, Geiger M, Binder BR. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 1999; 19: 1582–7.

Friedman JM. Leptin receptors and a control of body weight. Nutr Res 1998; 56: 38–46.

Mantzoros CS, Flier JS. Editorial: leptin as a therapeutic agent-trials and tribulations. J Clin Endocrinol Metab 2000; 85: 4000–2.

Heymsfield SB, Greenberg AS, Fujioka K et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, doseescalation trial. JAMA 1999; 282: 1568–75.

Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, Farid AR, Smith FJ, Campfield LA. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000; 85: 4003–9.

Westerterp-Plantenga MS, Saris WH, Huskhorn CJ, Campfield LA. Effects of weekly administration of pegylated recombinant human OB protein on appetite profile and energy metabolism in obese men. Am J Clin Nutr 2001; 74: 426–34.

Banks WA, Lebel CR. Strategies for the delivery of leptin to the CNS. J Drug Target 2002; 10: 297–308.

How to Cite
1.
Šabovič M, Mavri A. LEPTIN AND OBESITY – NEUROENDOCRINE , METABOLIC AND ATHEROGENIC EFFECTS OF LEPTIN. ZdravVestn [Internet]. 1 [cited 15Nov.2019];72(1). Available from: https://vestnik.szd.si/index.php/ZdravVest/article/view/1779
Section
Review